Global Metastatic Bone Disease Market - Snapshot

Metastatic bone disease can be quite agonizing to patients, both emotionally and financially, when they discover that their cancer has reached an advanced stage, thereby diminishing their chance of survival and adding to the treatment costs. According to the American Academy of Orthopedic Surgeons, nearly 50% of new cancer cases detected each year can spread (metastasize) to the skeleton. This leads to an additional treatment burden, with an estimated annual cost of US$ 12 Bn. The global metastatic bone disease market was valued at US$ 12,450.0 Mn in 2017 and is anticipated to reach US$ 24,886.8 Mn by 2026, expanding at a CAGR of 8.1% from 2018 to 2026. Rise in prevalence of cancers such as lung, breast, and prostate that metastasize to bones is anticipated to drive demand for metastatic bone cancer treatment during the forecast period from 2018 to 2026.

Rise in incidence rate of cancer across the world, favorable reimbursement scenario, stringent regulatory policies assuring better product quality, increase in cancer research funding and new drug approvals, and surge in cancer awareness programs by governments and patient support organizations propel the global metastatic bone disease market. However, high attrition rate in product development cycle and high research and development costs are the major factors restraining the global market.

metastatic-bone-disease-market.jpg

The global metastatic bone disease market has been segmented based on treatment, origin of metastasis, end-user, and region. In terms of treatment, the global market has been classified into medication, radiation therapy, surgical intervention, and tumor ablation therapy. The medication segment has been categorized into chemotherapy, hormone therapy, bisphosphonates, opiate therapy, and immunotherapy. Based on origin of metastasis, the global metastatic bone disease market has been divided into breast, lung, thyroid, kidney, prostate, and others. In terms of end-user, the global market has been classified into hospitals, specialty clinics, and ambulatory surgical centers. In terms of region, the global metastatic bone disease market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Based on treatment, the medication segment dominates the global metastatic bone disease market. Dominance of the segment is attributed to rise in prevalence of metastatic bone cancer and increase in preference among physicians to treat patients primarily with medication. Availability of various medication therapies such as chemotherapy, hormone therapy, and bisphosphonates is a major factor likely to propel the segment from 2018 to 2026. Radiation therapy is considered to be the second most prominent segment of the global metastatic bone disease market. The segment is likely to grow at a rapid pace owing to availability of well-qualified radiologists in developed countries and rise in need of radiation therapy for pain management in metastatic bone cancer.

In terms of origin of metastasis, the breast cancer segment dominated the global metastatic bone disease market in 2017 and the trend is likely to continue during the forecast period. Prevalence of breast cancer is rising due to an aging female population. According to the World Health Organization, breast cancer is the most common cancer in women in both developed and developing countries. This is due to increase in life expectancy, rise in urbanization, and adoption of western lifestyle. Prostate cancer is considered to be the second most prominent segment of the global metastatic bone disease market. Prostate cancer is the second most common cancer in men. An estimated 1.1 million men worldwide were diagnosed with prostate cancer in 2012. According to the American Cancer Society, nearly 1,685,210 new cancer cases were registered in the U.S. in 2016. Therefore, increase in number of cancer patients is expected to drive the prostate cancer segment from 2018 to 2026.

Based on end-user, the hospital segment dominates the global metastatic bone disease market. Hospitals are experiencing strong growth propelled by joint ventures, acquisitions, and provision of one-stop-shop services under one roof for various medical needs. Increase in number of hospitals, improvement in reimbursement policies, and increase in incidence of cancer are expected to drive the global metastatic bone disease market. The specialty clinics segment is likely to present significant opportunities in Asia Pacific.

In terms of region, North America and Europe accounted for combined market share of 60% in 2017. Improved health care infrastructure and rise in awareness about cancer and its treatment augment the market in Europe and North America. Increase in medical tourism is projected to drive the metastatic bone disease market in India. Technological advancements and availability of medical devices in Japan and China are anticipated to propel the market in these countries. Countries in Middle East & Africa are potential markets for metastatic bone disease treatments due to increase in incidence of cancer and advancement in technology.

Major players operating in the global metastatic bone disease market are Amgen, Inc., Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Eli Lilly and Company, Bayer AG, Fresenius Kabi AG, BTG plc, Boston Scientific Corporation, and Medtronic. These players adopt organic and in-organic growth strategies to expand product offerings, strengthen geographical reach, increase customer base, and capture market share.

Global Metastatic Bone Disease Market: Overview

This report analyzes the current and future scenario of the global metastatic bone disease market. Rise in incidence rate of cancer across the world, favorable reimbursement scenario, stringent regulatory policies assuring better product quality, increase in cancer research funding and new drug approvals, and surge in cancer awareness programs by governments and patient support organizations drive the global metastatic bone disease market. The global market has been segmented based on treatment, origin of metastasis, end-user, and region.

The global metastatic bone disease market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on treatment, origin of metastasis, end-user, and region. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the overview section. Additionally, the section comprises competitive matrix and company profiles along with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis by region and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the metastatic bone disease market.

Global Metastatic Bone Disease Market: Key Segments

Based on treatment, the global metastatic bone disease market has been segmented into medication, radiation therapy, surgical intervention, and tumor ablation therapy. The medication segment has been classified into chemotherapy, hormone therapy, bisphosphonates, opiate therapy, and immunotherapy. The market size and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year.

Based on origin of metastasis, the global metastatic bone disease market has been divided into breast, lung, thyroid, kidney, prostate, and others. The market size and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year.

In terms of end-user, the global the global metastatic bone disease market has been categorized into hospitals, specialty clinics, and ambulatory surgical centers. The segments have been analyzed based on health care infrastructure, government investment, and economic development in the regions. The market size and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year.

Global Metastatic Bone Disease Market: Regional Outlook

Geographically, the global metastatic bone disease market has been segmented into five major regions and the key countries in the respective region: North America (the U.S. and Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, and Rest of Asia Pacific), Latin America (Mexico, Brazil, and Rest of Latin America) and Middle East & Africa (South Africa, GCC Countries, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions.

Companies Mentioned in the Report

The report also profiles the major players in the market in terms of various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players operating in the global metastatic bone disease market are Amgen, Inc., Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Eli Lilly and Company, Bayer AG, Fresenius Kabi AG, BTG plc, Boston Scientific Corporation, and Medtronic. These players are adopting organic and inorganic growth strategies to expand product offerings, strengthen geographical reach, increase customer base, and garner market share.

The global metastatic bone disease market has been segmented as follows:

Global Metastatic Bone Disease Market, by Treatment

  • Medication
    • Chemotherapy
    • Hormone Therapy
    • Bisphosphonates
    • Opiate Therapy
    • Immunotherapy
  • Radiation Therapy
  • Surgical Intervention
  • Tumor Ablation Therapy

Global Metastatic Bone Disease Market, by Origin of Metastasis

  • Breast
  • Lung
  • Thyroid
  • Kidney
  • Prostate
  • Others

Global Metastatic Bone Disease Market, by End-user

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers

Global Metastatic Bone Disease Market, by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • India
    • Japan
    • China
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • South Africa
    • GCC Countries
    • Rest of Middle East & Africa
.